<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421590</url>
  </required_header>
  <id_info>
    <org_study_id>CSMC021C2208</org_study_id>
    <nct_id>NCT00421590</nct_id>
  </id_info>
  <brief_title>Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).</brief_title>
  <official_title>A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and Pharmacodynamics of SMC021 (0.8 mg Salmon Calcitonin/200 mg 5-CNAC) in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the effect of concomitant antacid on the pharmacokinetics and&#xD;
      pharmacodynamics of SMC021&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of concomitant antacid (calcium carbonate / magnesium hydroxide) on the pharmacokinetics and pharmacodynamics (decrease in serum CTX-I) of SMC021 (0.8 mg salmon calcitonin/200 mg 5-CNAC)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the tolerability of concomitantly-administered antacid and SMC021</measure>
  </secondary_outcome>
  <enrollment>38</enrollment>
  <condition>Health Postmenopausal Women</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMC021</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy postmenopausal female subjects, 40 to 70 years of age, and in good health as&#xD;
             determined by past medical history, physical examination, vital signs,&#xD;
             electrocardiogram, and laboratory tests at screening.&#xD;
&#xD;
          -  At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and&#xD;
             pulse rate) will be assessed after the subject has rested for at least three (3)&#xD;
             minutes. All blood pressure measurements at other time-points should be assessed with&#xD;
             the subject seated, and utilizing the same arm for each determination.&#xD;
&#xD;
          -  Postmenopausal women must have no regular menstrual bleeding for at least 5 years&#xD;
             prior to inclusion or must have been surgically sterilized at least 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Body mass index (BMI) must be within the range of 18 to 30. Subjects must weigh at&#xD;
             least 50 kg to participate in this study.&#xD;
&#xD;
          -  Able to communicate well with the investigator, to understand and comply with the&#xD;
             requirements of the study. Understand and sign the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers who report cigarette use of â‰¥ 5 cigarette per day. Smoking will not be allowed&#xD;
             on the days of each dosing up to the last blood sampling or the last assessment.&#xD;
&#xD;
          -  Use of any prescription drugs or over-the-counter (OTC) medication (vitamins, herbal&#xD;
             supplements, dietary supplements) started within the last month prior to screening.&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing, or less&#xD;
             than 10 times the corresponding half life of the drug taken.&#xD;
&#xD;
          -  The current or previous treatment that would affect bone metabolism/remodeling.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or&#xD;
             longer if required by local regulation.&#xD;
&#xD;
          -  Subjects with a hemoglobin level equal to or below 7.5 mmol/L at screening.&#xD;
&#xD;
          -  Significant illness within two weeks prior to dosing.&#xD;
&#xD;
          -  A past medical history of clinically significant ECG abnormalities or a family history&#xD;
             grandparents, parents and siblings) of a prolonged QT-interval syndrome.&#xD;
&#xD;
          -  History of autonomic dysfunction (e.g. history of fainting, orthostatic hypotension,&#xD;
             sinus arrhythmia).&#xD;
&#xD;
          -  History of acute or chronic bronchospastic disease (including asthma and chronic&#xD;
             obstructive pulmonary disease, treated or not treated),&#xD;
&#xD;
          -  History of clinically significant drug allergy or history of atopic allergy (asthma,&#xD;
             urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs&#xD;
             similar to the study drug.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs or which may jeopardize the subject in&#xD;
             case of participation in the study.&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  History of malignancy of any organ system within the past 5 years&#xD;
&#xD;
          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to dosing.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Randomized, partially blind, placebo controlled, crossover, drug interaction with concomitant antacid, pharmacokinetics, pharmacodynamics, SMC021</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

